Loading organizations...
Key people at Ekso Bionics.
Ekso Bionics is a Richmond, California-based company that develops and manufactures wearable exoskeletons designed to enhance human strength, endurance, and mobility for medical and industrial applications. Operating as a publicly traded entity on the NASDAQ under the ticker EKSO, the enterprise maintains a historical workforce of approximately 50 employees. The organization provides rehabilitation devices for patients with spinal cord injuries and neurological conditions, while also securing government contracts and strategic partnerships with entities such as DARPA, SOCOM, and the Stanford Research Institute. To further address upper extremity rehabilitation, the firm launched the EksoUE device in 2019. Expanding its product portfolio again, the company acquired the Human Motion and Control unit from Parker Hannifin in 2022, integrating the Indego exoskeleton line. Ekso Bionics was founded in 2005 by Nate Harding, Russ Angold, and Homayoon Kazerooni.
Ekso Bionics is a pioneering exoskeleton company that develops wearable robotic devices to enhance human mobility, primarily serving medical rehabilitation for patients with paralysis or spinal cord injuries and industrial workers needing strength augmentation.[1][4][7] Its key products include EksoNR and EksoGT for gait training in rehab settings, allowing users to stand and walk, and EksoUE and EksoVest for industrial load-bearing tasks.[1][2][3] The company solves critical problems like relearning to walk post-injury and reducing workplace musculoskeletal risks, with growth momentum shown through expansions into hospitals since 2015, product launches like EksoUE in 2020, and recent marketing-driven increases in conversions by 166.7% and organic visitors by 28.8%.[1][5]
Headquartered in Richmond, California (now with operations in San Rafael), Ekso Bionics went public in 2014 (NASDAQ: EKSO) and focuses on health and industrial sectors, emphasizing robotics to restore function and amplify abilities.[1][3][4][7]
Ekso Bionics originated in 2005 as Berkeley ExoWorks, founded by Homayoon Kazerooni, Russ Angold, and Nathan Harding from the University of California, Berkeley's Robotics and Human Engineering Laboratory.[1][2][3] The idea emerged from academic research into exoskeletons, starting with prototypes like ExoHiker and ExoClimber, which enabled able-bodied users to carry 150 pounds effortlessly.[1][2]
Renamed Berkeley Bionics in 2007, it advanced to the HULC (Human Universal Load Carrier), a hydraulic exoskeleton licensed to Lockheed Martin in 2009 for military use, marking early traction.[1][2][3] Pivoting to medical applications, it debuted eLEGS (later EksoGT) in 2011 for wheelchair users, with clinical testing in U.S. and European rehab centers.[1][2] The company renamed to Ekso Bionics, went public in 2014 amid funding challenges, and expanded into industrial products in 2015 while nearly closing in 2013 before securing government contracts.[1][3] Key moments include adding Variable Assist software in 2013 for adaptive power and launching EksoUE in 2020.[1]
Ekso Bionics stands out in the exoskeleton market through its broad expertise across medical, industrial, military, and research applications, developed over nearly two decades.[3][4][7]
Ekso Bionics rides the wave of wearable robotics and human augmentation, a trend exploding with aging populations, rising spinal injury rates (e.g., 250,000+ U.S. cases annually), and industrial demands for injury prevention amid labor shortages.[4][7] Timing aligns with FDA approvals for rehab exoskeletons since the 2010s and growing industrial adoption to cut workers' comp costs, positioning Ekso ahead of peers like ReWalk or Cyberdyne.[3]
Market forces favor it: healthcare robotics market projected to grow rapidly, with exoskeletons addressing rehab inefficiencies (e.g., faster walking recovery); industrial segment taps ergonomics regulations and e-commerce-driven logistics strain.[1][5][7] Ekso influences the ecosystem by pioneering civilian-to-military tech transfer, enabling R&D for global partners, and normalizing exoskeletons in hospitals and factories, fostering broader robotics innovation.[2][4]
Ekso Bionics is poised for expansion with maturing products like EksoNR in rehab and EksoVest in industry, potentially targeting at-home devices and upper-body worker aids amid rising telehealth and automation trends.[2][7] Leadership under CEO Scott Davis (since 2022) emphasizes scalability and partnerships, building on recent digital marketing wins.[4]
Shaping factors include AI-enhanced adaptive controls, insurance reimbursements for rehab, and industrial IoT integration for real-time ergonomics data. Its influence may evolve from niche pioneer to market leader if it narrows focus post-broad experimentation, driving human-robot symbiosis in health and work—echoing its founding mission to amplify natural abilities where biology falls short.[1][4][7]
Key people at Ekso Bionics.
